nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.02.2016 | Evidence-Based Review

Efficacy and Safety of 308-nm Monochromatic Excimer Lamp Versus Other Phototherapy Devices for Vitiligo: A Systematic Review with Meta-Analysis

verfasst von: Celso Lopes, Virginia Fernandes Moça Trevisani, Tamara Melnik

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Various phototherapy methods are used to treat vitiligo; however, the recent emergence of new devices has heightened debate concerning the best treatment method.

Objective

We aimed to systematically review and meta-analyze published data comparing the efficacy and adverse effects of monochromatic excimer lamps versus excimer laser and narrowband ultraviolet B (NB-UVB) in treating vitiligo.

Methods

A systematic search of PubMed, EMBASE, LILACS, Cochrane Central Register of Controlled Trials (CENTRAL), and clinical trials registries identified randomized controlled trials that included vitiligo patients, regardless of age, sex, or study language. We evaluated studies comparing excimer lamps with excimer laser or NB-UVB phototherapy.

Results

The review included six studies (411 patients, 764 lesions). No study found significantly different efficacy between excimer lamps and excimer laser using the outcomes of ≥50 % repigmentation [risk ratio (RR) = 0.97, 95 % confidence interval (CI) 0.84–1.11] and ≥75 % repigmentation (RR = 0.96, 95 % CI 0.71–1.30). Likewise, no study found significant differences between excimer lamps and NB-UVB (RR = 1.14, 95 % CI 0.88–1.48 for ≥50 % repigmentation; RR = 1.81, 95 % CI 0.11–29.52 for ≥75 % repigmentation). Adverse effects were mild, including pruritus, burning sensation, and dryness, none of which interrupted treatment.

Conclusions

To our knowledge, this is the first systematic review of the efficacy and safety of excimer lamp treatment for vitiligo. Excimer lamps, excimer laser, and NB-UVB are all safe and effective in repigmentation of vitiligo lesions. Safety, effectiveness, and cost are considerations when choosing treatment.

PROSPERO Registration Number

CRD42014015237.

Nur mit Berechtigung zugänglich

Lotti T, D’Erme AM. Vitiligo as a systemic disease. Clin Dermatol. 2014;32:430–4.PubMedCrossRef

Ding GZ, Zhao WE, Li X, Gong QL, Lu Y. A comparative study of mitochondrial ultrastructure in melanocytes from perilesional vitiligo skin and perilesional halo nevi skin. Arch Dermatol Res. 2015;307:281–9.PubMedCrossRef

Yaghoobi R, Omidian M, Bagherani N. Vitiligo: a review of the published work. J Dermatol. 2011;38:419–31.PubMedCrossRef

Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386:74–84.PubMedCrossRef

Taieb A, Alomar A, Böhm M, Dell’anna ML, De Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168:5–19.PubMedCrossRef

Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65:473–91.PubMedCrossRef

Teovska Mitrevska N, Eleftheriadou V, Guarneri F. Quality of life in vitiligo patients. Dermatol Ther. 2012;25:S28–31.

Sampogna F. Life course impairment and quality of life over time. Curr Probl Dermatol. 2013;44:47–51.PubMedCrossRef

Mishra N, Rastogi MK, Gahalaut P, Agrawal S. Dermatology specific quality of life in vitiligo patients and its relation with various variables: a hospital based cross-sectional study. J Clin Diagn Res. 2014;8:YC01–3.

10.

Krüger C, Schallreuter KU. Stigmatisation, avoidance behaviour and difficulties in coping are common among adult patients with vitiligo. Acta Derm Venereol. 2015;95:553–8.PubMedCrossRef

11.

Ezzedine K, Grimes PE, Meurant JM, Seneschal J, Léauté-Labrèze C, Ballanger F, et al. Living with vitiligo: results from a national survey indicate differences between skin phototypes. Br J Dermatol. 2015;173:607–9.PubMedCrossRef

12.

Bin Saif GA, Al-Balbeesi AO, Binshabaib R, Alsaad D, Kwatra SG, Alzolibani AA, et al. Quality of life in family members of vitiligo patients: a questionnaire study in Saudi Arabia. Am J Clin Dermatol. 2013;14:489–95.PubMedCrossRef

13.

Malhotra N, Dytoc M. The pathogenesis of vitiligo. J Cutan Med Surg. 2013;17:153–72.PubMedCrossRef

14.

Czajkowski R, Męcińska-Jundziłł K. Current aspects of vitiligo genetics. Postepy Dermatol Alergol. 2014;31:247–55.PubMedPubMedCentralCrossRef

15.

Spritz RA. Modern vitiligo genetics sheds new light on an ancient disease. J Dermatol. 2013;40:310–8.PubMedCrossRef

16.

Ghafourian A, Ghafourian S, Sadeghifard N, Mohebi R, Shokoohini Y, Nezamoleslami S, et al. Vitiligo: symptoms, pathogenesis and treatment. Int J Immunopathol Pharmacol. 2014;27:485–9.PubMed

17.

Speeckaert R, Speeckaert MM, van Geel N. Why treatments do(n’t) work in vitiligo: an autoinflammatory perspective. Autoimmun Rev. 2015;14:332–40.PubMedCrossRef

18.

Lin X, Tang LY, Fu WW, Kang KF. Childhood vitiligo in China: clinical profiles and immunological findings in 620 cases. Am J Clin Dermatol. 2011;12:277–81.PubMedCrossRef

19.

Laddha NC, Dwivedi M, Mansuri MS, Singh M, Gani AR, Yeola AP, et al. Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol. 2014;23:352–3.PubMedCrossRef

20.

Zedan H, Abdel-Motaleb AA, Kassem NM, Hafeez HA, Hussein MR. Low glutathione peroxidase activity levels in patients with vitiligo. J Cutan Med Surg. 2015;19:144–8.PubMed

21.

Güntaş G, Engin B, Ekmekçi ÖB, Kutlubay Z, Ekmekci H, Songür A, et al. Evaluation of advanced oxidation protein products, prooxidant-antioxidant balance, and total antioxidant capacity in untreated vitiligo patients. Ann Dermatol. 2015;27:178–83.PubMedPubMedCentralCrossRef

22.

Camara-Lemarroy CR, Salas-Alanis JC. The role of tumor necrosis factor-α in the pathogenesis of vitiligo. Am J Clin Dermatol. 2013;14:343–50.PubMedCrossRef

23.

Kumar R, Parsad D, Kanwar AJ. Role of apoptosis and melanocytorrhagy: a comparative study of melanocyte adhesion in stable and unstable vitiligo. Br J Dermatol. 2011;164:187–91.PubMedCrossRef

24.

Kumar R, Parsad D. Melanocytorrhagy and apoptosis in vitiligo: connecting jigsaw pieces. Indian J Dermatol Venereol Leprol. 2012;78:19–23.PubMedCrossRef

25.

Kanwar AJ, Mahajan R, Parsad D. Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg. 2013;17:259–68.PubMedCrossRef

26.

Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015;2:CD003263. doi:10.1002/14651858.CD003263.pub5.

27.

Du J, Wang XY, Ding XL, Xu QX, Chen Z, Chang JM, et al. Long-term efficacy and safety of tacrolimus ointment in the treatment of vitiligo. J Dermatol. 2013;40:935–6.PubMedCrossRef

28.

Cavalié M, Ezzedine K, Fontas E, Montaudié H, Castela E, Bahadoran P, et al. Maintenance therapy of adult vitiligo with 0.1 % tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135:970–4.PubMedCrossRef

29.

Newman MD, Silverberg NB. Once-daily application of calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for repigmentation of facial vitiligo. Cutis. 2011;88:256–9.PubMed

30.

Hossani-Madani A, Halder R. Treatment of vitiligo: advantages and disadvantages, indications for use and outcomes. G Ital Dermatol Venereol. 2011;146:373–95.PubMed

31.

Wong R, Lin AN. Efficacy of topical calcineurin inhibitors in vitiligo. Int J Dermatol. 2013;52:491–6.PubMedCrossRef

32.

Lim HW, Grimes PE, Lebwohl M. Indications and limitations of afamelanotide for treating vitiligo-reply. JAMA Dermatol. 2015;151:350.PubMedCrossRef

33.

Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151:42–50.PubMedCrossRef

34.

Singh C, Parsad D, Kanwar AJ, Dogra S, Kumar R. Comparison between autologous noncultured extracted hair follicle outer root sheath cell suspension and autologous noncultured epidermal cell suspension in the treatment of stable vitiligo: a randomized study. Br J Dermatol. 2013;169:287–93.PubMedCrossRef

35.

Bacigalupi RM, Postolova A, Davis RS. Evidence-based, non-surgical treatments for vitiligo: a review. Am J Clin Dermatol. 2012;13:217–37.PubMedCrossRef

36.

Machado Filho CD. Timoner FR. Epidermal curettage technique (ECT) for tissue harvest from the donor area for melanocyte autologous grafting in cases of vitiligo. An Bras Dermatol. 2014;89:681–3.PubMedPubMedCentralCrossRef

37.

Sapam R, Agrawal S, Dhali TK. Systemic PUVA vs. narrowband UVB in the treatment of vitiligo: a randomized controlled study. Int J Dermatol. 2012;51:1107–15.PubMedCrossRef

38.

Akar A, Tunca M, Koc E, Kurumlu Z. Broadband targeted UVB phototherapy for localized vitiligo: a retrospective study. Photodermatol Photoimmunol Photomed. 2009;25:161–3.PubMedCrossRef

39.

Yazdani Abyaneh M, Griffith RD, Falto-Aizpurua L, Nouri K. Narrowband ultraviolet B phototherapy in combination with other therapies for vitiligo: mechanisms and efficacies. J Eur Acad Dermatol Venereol. 2014;28:1610–22.

40.

Hallaji Z, Ghiasi M, Eisazadeh A, Damavandi MR. Evaluation of the effect of disease duration in generalized vitiligo on its clinical response to narrowband ultraviolet B phototherapy. Photodermatol Photoimmunol Photomed. 2012;28:115–9.PubMedCrossRef

41.

Akdeniz N, Yavuz IH, Gunes Bilgili S, Ozaydın Yavuz G, Calka O. Comparison of efficacy of narrow band UVB therapies with UVB alone, in combination with calcipotriol, and with betamethasone and calcipotriol in vitiligo. J Dermatolog Treat. 2014;25:196–9.PubMedCrossRef

42.

Alhowaish AK, Dietrich N, Onder M, Fritz K. Effectiveness of a 308-nm excimer laser in treatment of vitiligo: a review. Lasers Med Sci. 2013;28:1035–41.PubMedCrossRef

43.

Park KK, Liao W, Murase JE. A review of monochromatic excimer light in vitiligo. Br J Dermatol. 2012;167:468–78.PubMedCrossRef

44.

Lee BW, Schwartz RA, Hercogová J, Valle Y, Lotti TM. Vitiligo road map. Dermatol Ther. 2012;25(Suppl 1):S44–56.PubMedCrossRef

45.

Bulat V, Situm M, Dediol I, Ljubicić I, Bradić L. The mechanisms of action of phototherapy in the treatment of the most common dermatoses. Coll Antropol. 2011;35(Suppl 2):147–51.PubMed

46.

Lee CH, Wu SB, Hong CH, Yu HS, Wei YH. Molecular mechanisms of UV-induced apoptosis and its effects on skin residential cells: the implication in UV-based phototherapy. Int J Mol Sci. 2013;14:6414–35.PubMedPubMedCentralCrossRef

47.

Korobko IV. Review of current clinical studies of vitiligo treatments. Dermatol Ther. 2012;25(Suppl 1):S17–27.PubMedCrossRef

48.

Itoi S, Tanemura A, Nishioka M, Sakimoto K, Iimuro E, Katayama I. Evaluation of the clinical safety and efficacy of a newly developed 308-nm excimer lamp for vitiligo vulgaris. J Dermatol. 2012;39:559–61.PubMedCrossRef

49.

Mehraban S, Feily A. 308 nm excimer laser in dermatology. J Lasers Med Sci. 2014;5:8–12.

50.

Al-Shobaili HA. Treatment of vitiligo patients by excimer laser improves patients’ quality of life. J Cutan Med Surg. 2015;19:50–6.PubMedCrossRef

51.

Mouzakis JA, Liu S, Cohen G. Rapid response of facial vitiligo to 308nm excimer laser and topical calcipotriene. J Clin Aesthet Dermatol. 2011;4:41–4.PubMedPubMedCentral

52.

Welsh O, Herz-Ruelas ME, Gómez M, Ocampo-Candiani J. Therapeutic evaluation of UVB-targeted phototherapy in vitiligo that affects less than 10 % of the body surface area. Int J Dermatol. 2009;48:529–34. doi:10.1111/j.1365-4632.2009.03928.x.PubMedCrossRef

53.

Majid I. Efficacy of targeted narrowband ultraviolet B therapy in vitiligo. Indian J Dermatol. 2014;59:485–9.PubMedPubMedCentralCrossRef

54.

Kaliyadan F, Ashique KT. Optimizing the efficacy of targeted phototherapy by marking early vitiligo lesions after visualizing under a Wood’s lamp. J Am Acad Dermatol. 2014;71:e69.PubMedCrossRef

55.

Lotti TM, Hercogová J, Schwartz RA, Tsampau D, Korobko I, Pietrzak A, et al. Treatments of vitiligo: what’s new at the horizon. Dermatol Ther. 2012;25(Suppl 1):S32–40.PubMedCrossRef

56.

Hamzavi IH, Lim HW, Syed ZU. Ultraviolet-based therapy for vitiligo: what’s new? Indian J Dermatol Venereol Leprol. 2012;78:42–8.PubMedCrossRef

57.

Lee KY, Jeon SY, Hong JW, Choi KW, Lee CY, Choi SJ, et al. Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-α-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment. J Eur Acad Dermatol Venereol. 2013;27:609–16.PubMedCrossRef

58.

Noborio R, Morita A. Preferential induction of endothelin-1 in a human epidermal equivalent model by narrow-band ultraviolet B light sources. Photodermatol Photoimmunol Photomed. 2010;26:159–61.PubMedCrossRef

59.

Goldstein NB, Koster MI, Hoaglin LG, Spoelstra NS, Kechris KJ, Robinson SE, et al. Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors. J Invest Dermatol. 2015;135:2068–76.PubMedPubMedCentralCrossRef

60.

Eby JM, Kang HK, Tully ST, Bindeman WE, Peiffer DS, Chatterjee S, et al. CCL22 to activate treg migration and suppress depigmentation in vitiligo. J Invest Dermatol. 2015;135:1574–80.PubMedCrossRef

61.

Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration, 2011. http://handbook.cochrane.org. Accessed Oct 26 2015.

62.

Verhaeghe E, Lodewick E, van Geel N, Lambert J. Intrapatient comparison of 308-nm monochromatic excimer light and localized narrow-band UVB phototherapy in the treatment of vitiligo: a randomized controlled trial. Dermatology. 2011;223:343–8.PubMedCrossRef

63.

Casacci M, Thomas P, Pacifico A, Bonnevalle A, Paro Vidolin A, Leone G. Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311–313 nm) in the treatment of vitiligo–a multicentre controlled study. J Eur Acad Dermatol Venereol. 2007;21:956–63.PubMedCrossRef

64.

Shi Q, Li K, Fu J, Wang Y, Ma C, Li Q, et al. Comparison of the 308-nm excimer laser with the 308-nm excimer lamp in the treatment of vitiligo–a randomized bilateral comparison study. Photodermatol Photoimmunol Photomed. 2013;29:27–33.PubMedCrossRef

65.

Le Duff F, Fontas E, Giacchero D, Sillard L, Lacour JP, Ortonne JP, et al. 308-nm excimer lamp vs. 308-nm excimer laser for treating vitiligo: a randomized study. Br J Dermatol. 2010;163:188–92.PubMed

66.

Yan Y, Li J, Wang R, Zhong RP, Guo LH, Zhu MH. A randomized comparative clinical trial of 308 monochromatic excimer light and 311 nm narrow-band ultraviolet in treating vitiligo [in Chinese]. J Clin Dermatol. 2013;2:120–3.

67.

Liu YB, Yang YF, Song LX, Shan YH, Wang Y, Ma TQ, et al. Comparison of 308 nm excimer laser and 308 nm excimer lamp in treatment of vitiligo [in Chinese]. Clin Misdiagnosis Mistherapy. 2013;6:58–61.

68.

Lan CC, Yu HS, Lu JH, Wu CS, Lai HC. Irradiance, but not fluence, plays a crucial role in UVB-induced immature pigment cell development: new insights for efficient UVB phototherapy. Pigment Cell Melanoma Res. 2013;26:367–76.PubMedCrossRef

69.

Sun Y, Wu Y, Xiao B, Li L, Chen HD, Gao XH. Treatment of 308-nm excimer laser on vitiligo: a systemic review of randomized controlled trials. J Dermatolog Treat. 2015;26:347–53.PubMedCrossRef

70.

Xiao BH, Wu Y, Sun Y, Chen HD, Gao XH. Treatment of vitiligo with NB-UVB: a systematic review. J Dermatolog Treat. 2015;26:340–6.PubMedCrossRef

Titel: Efficacy and Safety of 308-nm Monochromatic Excimer Lamp Versus Other Phototherapy Devices for Vitiligo: A Systematic Review with Meta-Analysis
verfasst von: Celso Lopes
Virginia Fernandes Moça Trevisani
Tamara Melnik
Publikationsdatum: 01.02.2016
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 1/2016
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-015-0164-2

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusions

PROSPERO Registration Number

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials

Treatments for Cutaneous Lichen Planus: A Systematic Review and Meta-Analysis

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey

The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy

Mal de Meleda: A Focused Review